Japanese Drug Makers Switch To Reliance On Generics Sales
This article was originally published in PharmAsia News
Executive Summary
Several Japanese drug makers see greater opportunities in the generics market this year as major drugs begin losing patent protections. Some of the expirations are faced by Japanese makers themselves, including Daiichi Sankyo's bacteria fighter Cravit (levofloxacin) and Otsuka Pharmaceutical's ulcer treatment Mucosta (rebamipide). They, and AstraZeneca KK's cancer drug Casodex (bicalutamide) also losing its patent protection, boasted annual sales in the $500 million range. Sawai Pharmaceutical is set to take advantage of the expirations and a government emphasis on prescribing generics, with 34 generics set to be launched by the end of May. Towa Pharmaceutical plans 14 and Nichi-Iko Pharmaceutical 26. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.